Clinical trial
A Double-Blind, Placebo-Controlled, Phase 2B Study to Assess the Efficacy and Safety of a 14-Day Dosing Regimen of 3 Doses of ATB-346 Versus Placebo, Orally Administered Once Daily to Patients Diagnosed With Osteoarthritis of the Knee
NCT03978208 is registered in ClinicalTrials.gov with Antibe Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled, Phase 2B Study to Assess the Efficacy and Safety of a 14-Day Dosing Regimen of 3 Doses of ATB-346 Versus Placebo, Orally Administered Once Daily to Patients Diagnosed With Osteoarthritis of the Knee
- Lead sponsor
- Antibe Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 29, 2019
- Completion date
- December 29, 2019
- Enrollment
- 381 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.